Sacramento, CA -- March 21, 2018 -- InvestorsHub NewsWire -- A
new report has been published on Innovest Global, Inc. (OTC PINK:
IVST). Innovest Global, Inc. is a diversified holding company that
focuses on acquiring niche, high-growth businesses that are capable
of generating significant annual revenue. The company’s planned
subsidiaries operate across telehealth, biotech, commercial energy,
business-to-business distribution, national call center and auto
sales.
The report provides an overview of Innovest Global, Inc., its
subsidiaries, financials, industry analysis and more. The content
also covers brain and central nervous system (CNS) cancers and
associated statistics.
ABTA: Forecasts 80,000 New Cases of Primary Brain Tumors
This Year
Brain cancers seem to not receive the same level of attention
and awareness as other forms of the disease. However, in July
2017, Arizona Senator John McCain announced that he had
been diagnosed with an aggressive form of brain cancer,
glioblastoma. Glioblastomas are the most common form of brain
cancer in adults today.
“Glioblastoma can be difficult to treat. Average survival for
malignant glioblastoma tends to be about 14 months with treatment,”
says Dr. Sanjay Gupta, a practicing neurosurgeon.
As first-line treatments continue to focus on chemotherapy and
radiation, medical professionals are increasingly searching for
more advanced methods to treat these forms of cancer.
"The brain tumor community is very united in our quest for
finding better treatments for our patients, and I think the
progress will come through clearly planned and orchestrated
clinical trials, looking at both approaches, immunotherapies and
appropriate uses of targeted therapies, which will go and attack
the genes that drive a particular tumor," says Dr. Manmeet
Ahluwalia, a brain tumor oncologist and director of the brain
metastasis program at the Cleveland Clinic in Ohio.
According to the American Brain Tumor Association, an
estimated 80,000 new cases of primary brain tumors will be
diagnosed this year. Another 17,000 people are estimated to lose
their battle with a primary brain or CNS tumor this year.
According to GBI Research, global revenues for the cancer
vaccine market are forecast to grow from $2.5 billion in 2015 to
$7.5 billion in 2022, which represents a compound annual growth
rate (CAGR) of 16.93%.
Innovest Signs LOI to Acquire 20% Stake in StemVax, LLC,
a Biotech Company Working On Brain Cancer Vaccine
Innovest Global recently announced that it has signed a Letter
of Intent to acquire a 20% stake in StemVax, LLC, a
biotechnology company that is currently developing a brain cancer
vaccine.
The StemVax Glioblast (SVX-GB) cancer vaccine is being designed
and formulated to help restore a patient’s immune system in order
to fight off existing cancer cells within the body.
Adding to the excitement of the deal is the fact that Innovest
Global’s very own Dr. Dwain Morris-Irvin is the founder and CEO of
StemVax, LLC. Dr. Dwain is the CEO of Innovest’s new Biotechnology
& Health Sciences Division.
“Innovest is uniquely equipped to provide immeasurably important
elements to StemVax that kick things off for StemVax and
dramatically improve its potential for success. This is true for
other technologies we will encounter, as well. The best way I can
show future scientists how Innovest can serve their mission, is to
lead by example with my own company,” said Dr. Morris-Irvin. “Dan
Martin (Innovest Global CEO) and I have been planning the business
model for this division since 2017. It’s unique and will serve both
technologists and Innovest well.”
Aside from biotechnology, Innovest also recently announced that
its Innovest Energy Group has signed a Letter of Intent to acquire
an energy business that is producing annual revenues of
$1.2 million. The energy procurement acquisition target will
provide the Energy Division with new technologies and
synergies.
Once the energy acquisition is completed, management estimates
baseline quarterly revenues of $800,000. The Energy Division alone
will have more than 300 commercial and industrial clients and puts
Innovest Global in perfect position while the company gets started
on developing its Biotechnology & Health Sciences
Division.
Management continues to vet PCAOB auditors to be
engaged with the company and assist with auditing the financials.
This is in addition to the fact that the company’s corporate
counsel is an official OTCQX sponsor, which positions the company
to continue pursuing uplisting endeavors that have been laid out in
previous press releases.
For more information on Innovest Global, Inc., please
visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/03/20/this-company-is-working-on-a-brain-cancer-vaccine-that-would-help-fight-against-same-tumor-type-as-senator-john-mccains/
SpotlightGrowth.com is a digital hub for micro-caps,
small-caps, crowdfunding, cryptocurrency, and other emerging growth
investors. SpotlightGrowth.com serves as our media
subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third
party, to provide investor relations services for its
clients. Spotlight Growth creates exposure for companies
through a customized marketing strategy, including design of
promotional material, the drafting and editing of press releases
and media placement.
All information on featured companies is provided by the
companies profiled, or is available from public sources. Spotlight
Growth and its employees are not a Registered Investment Advisor,
Broker Dealer or a member of any association for other research
providers in any jurisdiction whatsoever and we are not qualified
to give financial advice. The information contained herein is based
on external sources that Spotlight Growth believes to be reliable,
but its accuracy is not guaranteed. Spotlight Growth may
create reports and content that has been compensated by a company
or third-parties, or for purposes of self-marketing. Spotlight
Growth was compensated two thousand five hundred dollars cash and
fifty thousand restricted shares for the creation and dissemination
of this content.
This material does not represent an investment solicitation.
Certain statements contained herein constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may include, without
limitation, statements with respect to the Company’s plans and
objectives, projections, expectations and intentions. These
forward-looking statements are based on current expectations,
estimates and projections about the Company’s industry,
management’s beliefs and certain assumptions made by
management.
The above communication, the attachments and external Internet
links provided are intended for informational purposes only and are
not to be interpreted by the recipient as a solicitation to
participate in securities offerings. Investments referenced
may not be suitable for all investors and may not be permissible in
certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and
employees may have bought or sold or may buy or sell shares in the
companies discussed herein, which may be acquired prior, during or
after the publication of these marketing materials. Spotlight
Growth, its affiliates, officers, directors, and employees may sell
the stock of said companies at any time and may profit in the event
those shares rise in value. For more information on our
disclosures, please
visit: http://spotlightgrowth.com/index.php/disclosures/
Contact: Matt Rego 9165257147 mrego@spotlightgrowth.com